New WHO-UNITAID briefing paper: Improving Access to Covid-19 Treatments
A new briefing paper based on Medicines Law & Policy research outlines the legal instruments available for countries seeking to access key therapeutics to...
Medicines Law & Policy Intervention at the WHO Pandemic Accord Negotiations
This statement was delivered on 19 February at the World Health Organization in Geneva, on the occasion of the 8th Intergovernmental Negotiating Body to...
The European Commission’s proposal on a new EU-wide compulsory licensing regime
Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London
A recent international health emergency, the...
Will Europe block the Pandemic Agreement because of one word?
This commentary originally appeared in the Brussels Times, and is available here.
The Pandemic Agreement negotiations began in December of 2021. Sufficiently motivated by the...
Urgent collective action to meet the challenge of this pandemic crisis: a coronavirus related...
The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, first described the present coronavirus (COVID-19) outbreak as a pandemic on the 11th...
The new IP strategy of war-torn Ukraine should prioritise public health and national security
Russia’s full-scale assault on Ukraine continues for the third year. The Russian occupation forces have already killed tens of thousands of civilians, including children. They have...
Dutch Minister of Health writes open letter to pharma, threatens to name and shame
"Dear Pharma," writes the Dutch Minister of Health, Bruno Bruins in an open letter in the daily newspaper the Volkskrant, "Last week two messages jumped...
European Pharmaceutical Legislation Needs Exceptions to Data and Market Exclusivity to Protect European Patients...
On 11 May 2018, US President Trump announced his plans to lower drug prices in America. Under the banner "American Patients First" he outlined...
Covid-19 and the comeback of compulsory licensing
The Covid-19 outbreak raises many questions, including some we can answer using experiences gained in previous disease outbreaks. Here is one: how to deal...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...